All In Biotech

NDA 017116 · Specgx LLC

Methadose

Methadone Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1973

Mar 14, 1973

Approved uses

1

Original approval plus efficacy supplements

Registered trials

340

70 Phase 3, 35 recruiting

FAERS reports

10,902

9,376 serious, 3,064 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION, LIFE-THREATENING QT PROLONGATION, ACCIDENTAL INGESTION, ABUSE POTENTIAL, INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES and TREATMENT FOR OPIOID ADDICTION Life-Threatening Respiratory Depression Respiratory depression, including fatal cases, have been reported during initiation and conversion of patients to methadone, and even when the drug has been used as recommended and not misused or abused [see Warnings and Precautions ( 5.1 )]. Proper dosing and titration are essential and METHADOSE should only be prescribed by healthcare professionals who are knowledgeable in the use of methadone for detoxification and maintenance treatment of opioid addiction. Monitor for respiratory depression, especially during initiation of METHADOSE or following a dose increase. The peak respiratory depressant effect of methadone occurs later,...

What it is approved for

From the label in effect Apr 27, 2026.

METHADOSE contains methadone, an opioid agonist indicated for the: detoxification treatment of opioid addiction (heroin or other morphine-like drugs). maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Limitations of Use Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 21 CFR, Title 42, Sec 8 [see Dosage and Administration ( 2.1 )] . METHADOSE is an opioid agonist indicated for the: Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). ( 1 ) Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. ( 1 ) Limitations of Use Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 21 CFR, Title 42, Sec. 8. ( 1 , 2.1 )

Mechanism: Methadone hydrochloride is a mu-agonist; a synthetic opioid with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The methadone withdrawal syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone’s efficacy is...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • METHADOSE · METHADONE HYDROCHLORIDE 10MG/ML · CONCENTRATE, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Methadone" as an intervention, any sponsor and status, largest first.

All 340 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal exposure during pregnancy1,458
  • drug withdrawal syndrome neonatal1,434
  • toxicity to various agents1,220
  • drug dependence1,031
  • overdose945
  • drug abuse801
  • death587
  • pain553
  • maternal exposure during pregnancy536
  • dependence535
  • developmental delay507
  • learning disability465

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004141
2005150
2006133
2007105
2008156
2009285
2010218
2011493
20121,020
2013454
2014156
2015213
2016154
2017276
2018679
2019604
2020720
20211,231
2022864
2023946
2024888
2025618
2026397

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Methadose (Methadone HCl)

2024 spending

$8K

Beneficiaries

153

439 claims

Per beneficiary

$51

$0.10 per unit

View as table
YearSpending
2020$7,258
2021$4,206
2022$5,561
2023$7,567
2024$7,856

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,076 on PubMed

Sponsor: Specgx LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.